AEZS News and Press, Aeterna Zentaris Inc. From 03/29/22

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) -- Aeterna...

Aeterna Zentaris (NASDAQ:AEZS) said that enrollment of a phase 3 trial of macimorelin in childhood-onset growth hormone deficiency is delayed due to ongoing impacts from COVID-19 and the situation between Ukraine and Russia. The company said that recruitment of the AEZS-130-P02 trial "may now...

– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TO...

Aeterna Zentaris (NASDAQ:AEZS) expanded its existing research program with the Julius-Maximilians-University Wuerzburg (JMU) on the development of COVID-19 and Chlamydia trachomatis vaccines. The expanded research activities will use JMU’s program involving 3D models of human intestina...

– R esearch agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or ...

Aeterna Zentaris (AEZS +7.7%) said its licensor, The University of Sheffield received a notice of allowance from the U.S. Patent and Trademark Office (USPTO). The patent application No. 16/608,611, entitled, “Parathyroid Hormone Fusion Polypeptide” includes claims...

– Notice of allowance received by Company’s l icensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism – TORONTO, ONTARIO, Marc...

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic pr...

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ...

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharma...